The development of TLR antagonists for therapy of hepatic fibrosis and cirrhosis
Ended Project Grant Awarded Last action
- Award ID
- R41DK101221
- Recipient
-
Dynavax Technologies Corporation UEI JA7GSG397PL1
- Awarding agency
-
National Institutes of Health
Department of Health and Human Services
- Obligated
- $223,390
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Place of performance
- Berkeley, CA 94710, USA
Award details come from USAspending.gov.
Quick answers
Who received award R41DK101221?
R41DK101221 was awarded to Dynavax Technologies Corporation by National Institutes of Health (Department of Health and Human Services) on September 25, 2013.
How much is award R41DK101221 worth?
$223,390 has been obligated on R41DK101221.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award